In this report, we show that the BAD pathway expression can differentiate between triple-negative phenotype breast cancers and those that express ER and/or PR in tumours and cell lines; furthermore, the BAD pathway expression was found to be associated with OS in 2 independent clinico-genomic datasets. Here, BAD is linked to breast cancer.